Difficult-to-control asthma in adults is under-diagnosed and under-treated in the United States, particularly in those 40 years of age or older. Increasing attention has been focused on the subset of adult patients with poorly controlled asthma because they consume up to 85% of all health care dollars spent on asthma, while representing 20% of all asthma patients. In this article, we define difficult-to-control asthma and discuss the problem of misdiagnosis. We present an algorithm for confirming the diagnosis in these patients and highlight the importance of patient self-assessment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjmed.2006.10.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atopic dermatitis.
Allergy Asthma Clin Immunol
December 2024
Division of Allergy, IWK Health Centre, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life (QoL) of affected individuals as well as their families. Although the pathogenesis of the disorder is not yet completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient's history and clinical manifestations.
View Article and Find Full Text PDFIntroduction: Patients with uncontrolled, moderate-to-severe asthma have a higher risk for exacerbations, negatively impacting lung function and quality of life. Dupilumab, a fully human monoclonal antibody, blocks interleukins 4 and 13, key and central drivers of type 2 inflammation. Dupilumab has been effective in the treatment of certain types of moderate-to-severe asthma across several clinical trials.
View Article and Find Full Text PDFCritical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody.
Allergol Int
January 2025
Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan.
Characteristic symptoms of NSAID-exacerbated respiratory disease (N-ERD) include asthma, chronic eosinophilic rhinosinusitis with nasal polyposis, cysteinyl LT (CysLT) overproduction and NSAIDs hypersensitivity. Some N-ERD patients present with episodic treatment-resistant extra-respiratory symptoms (CysLT-associated coronary artery vasospasm, gastroenteritis, or skin rash). Even when using standard treatments for respiratory and extra-respiratory symptoms, including systemic corticosteroids and aspirin desensitization, it is difficult to control the clinical symptoms and severe type 2 inflammation involved with mast cells, eosinophils, ILC2s, and platelet activation.
View Article and Find Full Text PDFAsthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations.
Immunol Allergy Clin North Am
November 2024
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA; Division of Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Article Synopsis
- The past two decades have seen significant advancements in asthma treatment with the development of targeted biologic therapies.
- There are currently six monoclonal antibodies designed to target specific inflammatory mediators involved in asthma, allowing for more personalized treatment options.
- These therapies include omalizumab (anti-IgE), mepolizumab and reslizumab (anti-IL-5), benralizumab (IL-5 receptor antagonist), dupilumab (IL-4 receptor antagonist), and tezepelumab (anti-thymic stromal lymphopoietin).
Electronic cigarettes: "wolves in sheep's clothing".
J Pediatr (Rio J)
September 2024
Diretor Científico - Sociedade Brasileira de Pediatria (SBP), São Paulo, SP, Brazil.
Objective: To provide cutting-edge information on the impact and risks of using Electronic Nicotine Delivery Systems (ENDS) by children and adolescents, based on the latest evidence published in the literature.
Data Source: A comprehensive search was carried out on PubMed, using the expressions ''electronic cigarettes'' OR ''electronic nicotine delivery systems" OR "vaping" AND ''adolescent'' AND "risks" AND ''acute lung injury'. All retrieved articles had their titles and abstracts read to identify and fully read the papers reporting the most recent evidence on each subject.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!